Abstract Number: 2032 • 2013 ACR/ARHP Annual Meeting
How Does Age At Onset Influence Autoimmune Rheumatic Diseases?
Background/Purpose: Age at onset of disease (AOD) refers to the time period at which a patient experiences the first sign (s) and symptom(s). AOD varies…Abstract Number: 2033 • 2013 ACR/ARHP Annual Meeting
Mortality Prognostic Factors Of Patients With Systemic Autoimmune Diseases Admitted To An Intensive Care Unit
Background/Purpose: To identify mortality prognostic factors of patients with systemic autoimmune diseases (SAD) admitted in a medical intensive care unit (ICU). Methods: Retrospective observational study…Abstract Number: 2034 • 2013 ACR/ARHP Annual Meeting
Does Mixed Connective Tissue Disease Or Sharp’s Syndrome Really Exist?
Background/Purpose: The existence of Mixed Connective Tissue Disease (MCTD) has often been discussed in literature and its diagnostic criteria are very heterogeneous. Anti-U1-RNP antibodies are…Abstract Number: 2035 • 2013 ACR/ARHP Annual Meeting
Description Of 142 Cases Of Relapsing Polychondritis Followed In a Single Center Since 2000
Background/Purpose: Relapsing polychondritis (RP) is a rare condition characterized by recurrent inflammation of cartilaginous tissues and systemic manifestations. Data on prognosis available from the latest…Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…Abstract Number: 2037 • 2013 ACR/ARHP Annual Meeting
Isolated Anti-Ro52 Antibody – Significance and Clinical Association
Isolated anti-Ro52 antibody – significance and clinical association Background/Purpose: Antibodies against Ro-52 (TRIM21) have been described in patients with a broad spectrum of autoimmune diseases. Anti-Ro52…Abstract Number: 2038 • 2013 ACR/ARHP Annual Meeting
Congenital Heart Block Related With Maternal Autoimmune Diseases: Descriptive Analysis Of a Series Of 17 Cases
Background/Purpose: To describe the clinical characteristics of maternal autoimmune-mediated fetal congenital heart block (CHB) in a cohort of pregnant women from an Autoimmune Diseases Pregnancy…Abstract Number: 2039 • 2013 ACR/ARHP Annual Meeting
Micro and Nanoparticles As Possible Causative-Prognostic Co-Factors Of Mixed Cryoglobulinemia Syndrome
Background/Purpose: We previously demonstrated that patients affected by membranoproliferative glomerulonephritis and mixed cryoglobulinemia syndrome (MCs) show the presence of circulating micro and nanoparticles (MPs and…Abstract Number: 2040 • 2013 ACR/ARHP Annual Meeting
Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Background/Purpose: Associations between chronic urticaria (CU) with autoantibodies and other autoimmune conditions have implicated T cells in CU initiation and/or propagation. Many patients (pts) have…Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…Abstract Number: 2043 • 2013 ACR/ARHP Annual Meeting
Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes
Background/Purpose: Despite the high incidence of rheumatic diseases during reproductive years, little is known about the perinatal impact of traditional and biologic disease modifying antirheumatic…Abstract Number: 2044 • 2013 ACR/ARHP Annual Meeting
Birth Outcomes In Childbearing Women Treated With Thiopurines: A Meta-Analysis
Background/Purpose: The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) are effective treatments for many rheumatic and autoimmune conditions. These medications have a category D classification from…Abstract Number: 2045 • 2013 ACR/ARHP Annual Meeting
Long QT and Hydroxychloroquine; A Poorly Recognised Problem In Rheumatology Patients
Background/Purpose: Hydoxychloroquine (HCQ) is widely used for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) with a side-effect profile including myopathy…Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies
Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
ACR Meeting Abstracts